Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661013 | 0.84 | TSHR (0.41) | TSHRTP53ALDH1A1HCRTR2KDM4E | |
| SCHEMBL12448260 | 0.84 | TSHR (0.41) | TSHRTP53ALDH1A1HCRTR2KDM4E | |
| SCHEMBL8299606 | 0.79 | TP53 (0.46) | TSHRTP53ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL22893218 | 0.79 | USP30 (0.31) | HCRTR2 | |
| SCHEMBL15299196 | 0.75 | TP53 (0.39) | TSHRTP53 | |
| SCHEMBL8077317 | 0.75 | TSHR (0.37) | TSHRTP53ALDH1A1HCRTR2KDM4E | |
| SCHEMBL15262870 | 0.73 | TP53 (0.34) | TP53 | |
| SCHEMBL12448261 | 0.72 | CA1 (0.33) | SMN1; SMN2 | |
| SCHEMBL14737225 | 0.71 | TSHR (0.35) | TSHRCYP2D6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24615847 | 0.70 | TP53 (0.32) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TSHR 2808/4885TP53 163/4885ALDH1A1 4260/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TSHR 2808/4885TP53 163/4885ALDH1A1 4260/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TSHR 2808/4885TP53 163/4885ALDH1A1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.